Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Subclinical Atherosclerosis in Psoriatic Arthritis
NCT07251556Phase 4Not yet recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Dec 2025
- Primary completion
- Jan 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 4, randomised, open-label trial of semaglutide in atherosclerosis (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoint: Carotid Intima-Media Thickness at 24 weeks. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT07251556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07251556.